EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 4.0

Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation in Refractory Angina

Utkarsh Ojha, Muhammad Mohsin, Krzysztof Macierzanka, Fiyyaz Ahmed-Jushuf, Christopher A Rajkumar, Shayna Chotai, Florentina A Simader, Matthew J Shun-Shin, Michael J Foley, Rasha K Al-Lamee

JACC: Cardiovascular Interventions · 2025

DOI: 10.1016/j.jcin.2025.06.012 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JACC: Cardiovascular Interventions, 2025. Verfasst von Utkarsh Ojha und 9 weiteren Autor:innen. Beteiligte Einrichtung: East Kent Hospitals University NHS Foundation Trust, Queen Elizabeth The Queen Mother Hospital, Margate, United Kingdom. Hauptthemen laut MEDLINE: Coronary Sinus, Angina Pectoris, Cardiac Catheterization. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Previous coronary sinus reducer (CSR) meta-analyses in refractory angina (RA) focused on single-arm studies, capturing observed effectiveness-comprising the physical effect of CSR, contextual effects (eg, placebo), and non-treatment-related phenomena (eg, confounding). Efficacy evaluation requires comparative estimates from randomized controlled trials (RCTs), ideally double blind and placebo controlled, to isolate the physical effect. OBJECTIVES: The aims of this study were to evaluate the safety and efficacy of CSR in RA and to compare its efficacy with observed effectiveness. METHODS: The study was preregistered with the International Prospective Register of Systematic Reviews (CRD42023399099). Electronic databases were searched until April 2024. Random-effects models separately pooled single-arm, isolated RCT intervention-arm, and RCT placebo-controlled estimates. Therapeutic outcomes included improvements in Canadian Cardiovascular Society classification, Seattle Angina Questionnaire scores, and treadmill exercise time. Safety outcomes, summarized descriptively, comprised procedural success and adverse events. RESULTS: Three double-blind, placebo-controlled RCTs (n = 180) and 13 single-arm studies (n = 668) were analyzed. The overall unweighted procedural success rate was 98.3% (95% CI: 97.0%-99.1%). Single-arm studies and RCT intervention arms demonstrated statistically significant improvements across therapeutic outcomes. For Canadian Cardiovascular Society classification, placebo-controlled rates were 26% (95% CI: 11%-38%; P < 0.001) for ≥1-class improvement and 17% (95% CI: 2%-37%; P = 0.02) for ≥2-class improvement, representing approximately one-third of single-arm improvement rates. Seattle Angina Questionnaire domain analyses demonstrated insufficient placebo-controlled evidence of benefit. Placebo-controlled exercise time change was 49.62 seconds (95% CI: 1.84-97.40 seconds; P = 0.04). CONCLUSIONS: CSR implantation is safe and feasible and demonstrates promising antianginal efficacy in patients with RA. However, uncertainty in current efficacy findings and susceptibility of effectiveness data to nonphysical influences preclude definitive conclusions about clinical utility, warranting larger placebo-controlled trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary SinusAngina PectorisCardiac CatheterizationHumansTreatment OutcomeMiddle AgedMaleFemaleAgedRandomized Controlled Trials as TopicRisk FactorsTime FactorsRecovery of FunctionExercise Tolerance

Stichwörter der Autor:innen

coronary sinus reducereffectivenessefficacymeta-analysisrefractory anginasafety

Autor:innen und Institutionen

  • East Kent Hospitals University NHS Foundation Trust, Queen Elizabeth The Queen Mother Hospital, Margate, United Kingdom.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom; Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom.
  • National Heart and Lung Institute, Imperial College London, London, United Kingdom; Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, United Kingdom. Electronic address: r.al-lamee13@imperial.ac.uk.

Zitieren

APA

Ojha, U., Mohsin, M., Macierzanka, K., Ahmed-Jushuf, F., Rajkumar, C. A., Chotai, S., Simader, F. A., Shun-Shin, M. J., Foley, M. J., & Al-Lamee, R. K. (2025). Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation in Refractory Angina. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2025.06.012

Vancouver

Ojha U, Mohsin M, Macierzanka K, Ahmed-Jushuf F, Rajkumar CA, Chotai S, et al. Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation in Refractory Angina. JACC: Cardiovascular Interventions. 2025. doi:10.1016/j.jcin.2025.06.012

BibTeX
@article{Ojha2025,
  author = {Ojha, Utkarsh and Mohsin, Muhammad and Macierzanka, Krzysztof and Ahmed-Jushuf, Fiyyaz and Rajkumar, Christopher A and Chotai, Shayna and Simader, Florentina A and Shun-Shin, Matthew J and Foley, Michael J and Al-Lamee, Rasha K},
  title = {Safety, Efficacy, and Effectiveness of Coronary Sinus Reducer Implantation in Refractory Angina},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  doi = {10.1016/j.jcin.2025.06.012}
}
Kostenlos starten →